Compare CCTG & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCTG | RDHL |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.6M |
| IPO Year | 2024 | N/A |
| Metric | CCTG | RDHL |
|---|---|---|
| Price | $0.11 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 21.2M | 1.3M |
| Earning Date | 12-26-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,878,618.00 | $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.52 | ★ 157.62 |
| 52 Week Low | $0.11 | $0.91 |
| 52 Week High | $2.61 | $6.80 |
| Indicator | CCTG | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 29.80 | 57.48 |
| Support Level | $0.11 | $1.20 |
| Resistance Level | $0.17 | $1.38 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 3.36 | 82.54 |
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas, Asia, and Others.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.